Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

Clinical Gastroenterology and Hepatology

Volumn 2, Issue 7, 2004, Pages 542-553

  Hanauer, Stephen B ^a   Wagner, Carrie L ^b   Bala, Mohan ^b   Mayer, Lloyd ^c   Travers, Suzanne ^b   Diamond, Robert H ^b   Olson, Allan ^b   Bao, Warren ^b   Rutgeerts, Paul ^d  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b CENTOCOR INC   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

6 mercaptopurine; 6 MP; a Crohn's disease clinical trial evaluating infliximab in a new long term treatment regimen in patients with Crohn's disease; ACCENT I; ACR20 50; American College of Rheumatology definition of 20 or 50 improvement; ATTRACT

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PLACEBO;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EVALUATION; FEMALE; HUMAN; IMMUNOMODULATION; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; RANDOMIZED CONTROLLED TRIAL; REMISSION; SERUM SICKNESS; SINGLE DRUG DOSE;

ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; PROBABILITY; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 3042579454     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1542-3565(04)00238-1     Document Type: Article

References (21)

1. Gura T. Magic bullets hit the target. Nature. 417:2002;584-586
2. Fineberg S.E., Galloway J.A., Fineberg N.S., Rathbun M.J., Hufferd S. Immunogenicity of recombinant DNA human insulin. Diabetologia. 25:1983;465-469
3. Bray G.L., Gomperts E.D., Courter S., Gruppo R., Gordon E.M., Manco-Johnson M., Shapiro A., Scheibel E., White G. 3rd, Lee M. Multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A: the Recombinate Study Group. Blood. 83:1994;2428-2435
4. Knight D.M., Trinh H., Le J., Siegel S., Shealy D., McDonough M., Scallon B., Moore M.A., Vilcek J., Daddona P., Ghrayeb J. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 30:1993;1443-1453
5. LoBuglio A.F., Wheeler R.H., Trang J., Haynes A., Rogers K., Harvey E.B., Sun L., Ghrayeb J., Khazaeli M.B. Mouse/human chimeric monoclonal antibody in man kinetics and immune response. Proc Natl Acad Sci U S A. 86:1989;4220-4224
6. Kindler V., Sappino A.P., Grau G.E., Piquet P.F., Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell. 56:1989;731-740
7. Braegger C.P., Nicholls S., Murch S.H., Stephens S., MacDonald T.T. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet. 339:1992;89-91
8. Breese E.J., Michie C.A., Nicholls S.W., Murch S.H., Williams C.B., Domizio P., Walker-Smith J.A., MacDonald T.T. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology. 106:1994;1455-1466
9. MacDonald T.T., Hutchings P., Choy M.Y., Murch S., Cooke A. Tumor necrosis factor-alpha and interferon gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol. 81:1990;301-305
10. Schreiber S., Nikolaus S., Hampe J., Hamling J., Koop I., Groessner B., Lochs H., Raedler A. Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease. Lancet. 353:1999;459-461
11. Maini R.N., Elliott M.J., Brennan F.M., Williams R.O., Chu C.Q., Paleolog E., Charles P.J., Taylor P.C., Feldmann M. Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol Rev. 144:1995;195-223
12. Feldmann M., Brennan F.M., Maini R.N. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 14:1996;397-440
13. Chaudhari U., Romano P., Mulcahy L.D., Dooley L.T., Baker D.G., Gottlieb A.B. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis a randomised trial. Lancet. 357:2001;1842-1847
14. Partsch G., Steiner G., Leeb B.F., Dunky A., Broll H., Smolen J.S. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol. 24:1997;518-523
15. Maini R.N., Breedveld F.C., Kalden J.R., Smolen J.S., Furst D., Weisman M.H., St. Clair E.W., van der Heijde D., Keenan G., Marsters P., Lipsky P.E. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis With Concomitant Therapy Study Group. Sustained improvement over two years in physical function, structural damage and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. 50:2004;1051-1065
16. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., Rachmilewitz D., Wolf D.C., Olson A., Bao W., Rutgeerts P. ACCENT I Study Group. Maintenance infliximab for Crohn's disease the ACCENT I randomised trial. Lancet. 359:2002;1541-1549
17. Best W.R., Becktel J.M., Singleton J.W., Kern F. Jr. Development of a Crohn's Disease Activity Index National Cooperative Crohn's Disease Study. Gastroenterology. 70:1976;439-444
18. Maini R.N., Breedveld F.C., Kalden J.R., Smolen J.S., Davis D., Macfarlane J.D., Antoni C., Leeb B., Elliott M.J., Woody J.N., Schaible T.F., Feldmann M. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41:1998;1552-1563
19. Stein K. Immunogenicity of protein products. Presented at Biological Response Modifiers Advisory Committee, FDA Center for Biological Evaluation and Research (CBER): preclinical and clinical development of biological therapeutics: focus on pharmacokinetics and pharmacodynamics. 1999;. Rockville, MD: July 15
20. Farrell R.J., Alsahli M., Jeen Y.-.T, Falchuk K.R., Peppercorn M.A., Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease a randomized trial. Gastroenterology. 124:2003;917-924
21. Baert F., Noman M., Vermeire S., Van Assche G., D'Haens G., Carbonez A., Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 348:2003;601-608